KYMERA THERAPEUTICS INC (KYMR)

Kymera Therapeutics, Inc. - Phase 1b Trial Data Expected

Kymera Therapeutics, Inc. plans to advance its investigational oral degrader of STAT6, KT-621, into a Phase 1b clinical trial for atopic dermatitis (AD) patients, expecting data by Q4 2025. The drug is currently undergoing a Phase 1 trial in healthy volunteers, with preliminary results anticipated in Q2 2025. Additional Phase 2b trials in AD and asthma are projected to start in late 2025 and early 2026, respectively. The strategic goal of these trials is to leverage KT-621's potential in immunological applications, specifically in treating AD and asthma.

Initiation of Parallel Phase 2b Clinical Trials for KT-621

Kymera Therapeutics, Inc. plans to initiate parallel Phase 2b clinical trials of KT-621, an investigational oral degrader of STAT6, for atopic dermatitis and asthma in late 2025 and early 2026. The company anticipates data from a Phase 1 clinical trial for KT-621 in healthy volunteers in the second quarter of 2025, with further Phase 1b trial data in atopic dermatitis expected by the end of 2025. Kymera's strategic focus includes advancing its immunology portfolio, supported by an estimated cash balance of approximately $850 million as of December 31, 2024. These developments are part of the company’s objectives for 2025 and will be highlighted during upcoming presentations at the J.P. Morgan Healthcare Conference.

Expected Completion of Clinical Trial for KT-621 in Atopic Dermatitis

Kymera Therapeutics, Inc. announced it is advancing KT-621, an investigational oral degrader of STAT6, into a Phase 1b clinical trial for atopic dermatitis (AD) patients in Q2 2025, with data expected by Q4 2025. The company has also indicated plans to initiate parallel Phase 2b trials for KT-621 in AD and asthma in late 2025 and early 2026. The Phase 1 trial in healthy volunteers is currently ongoing with preliminary data anticipated in mid-2025. This development is a strategic move to enhance Kymera's portfolio in immunology, which could have significant implications for patient treatment in AD and asthma.

Expected Completion of Phase 2 Study of SAR444656

Sanofi's Phase 2 clinical trial of SAR444656 for treating moderate to severe Hidradenitis Suppurativa is expected to complete on July 17, 2026. The study, which is currently recruiting, aims to assess the efficacy, safety, pharmacokinetics, and biological effects of SAR444656 in adult participants aged 18 to 70 years. The trial will involve a total duration of up to 24 weeks, including treatment and follow-up phases, and aims to enroll 156 participants. This research could have significant implications for investors monitoring developments in therapies for Hidradenitis Suppurativa, an inflammatory skin condition.

• www.clinicaltrials.gov/study/NCT06028230

Expected Completion of Phase 2 Study of SAR444656 in Atopic Dermatitis

Sanofi's Phase 2 study of SAR444656 for moderate to severe atopic dermatitis is expected to complete on August 18, 2026. The study involves 200 adult participants who are inadequately controlled by topical treatments or for whom such treatments are inadvisable. They will be randomized to receive either SAR444656 or a placebo over a 24-week period. Given its design as a multicenter, double-blind, placebo-controlled trial, the outcomes could provide significant insights into the drug's efficacy and safety, potentially affecting future treatment protocols and market dynamics for atopic dermatitis therapies.

• www.clinicaltrials.gov/study/NCT06058156